Reliance Trust Co. of Delaware lowered its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.5% during the first quarter, Holdings Channel reports. The institutional investor owned 11,321 shares of the pharmaceutical company’s stock after selling 167 shares during the period. Reliance Trust Co. of Delaware’s holdings in Vertex Pharmaceuticals were worth $1,238,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Jennison Associates LLC boosted its stake in shares of Vertex Pharmaceuticals by 74.2% in the third quarter. Jennison Associates LLC now owns 5,180,761 shares of the pharmaceutical company’s stock valued at $451,814,000 after buying an additional 2,205,961 shares in the last quarter. Norges Bank bought a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at $127,564,000. Camber Capital Management LLC bought a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at $55,253,000. Two Sigma Investments LP boosted its stake in shares of Vertex Pharmaceuticals by 143.1% in the fourth quarter. Two Sigma Investments LP now owns 1,026,855 shares of the pharmaceutical company’s stock valued at $75,648,000 after buying an additional 604,506 shares in the last quarter. Finally, Capital World Investors boosted its stake in shares of Vertex Pharmaceuticals by 2.8% in the third quarter. Capital World Investors now owns 22,292,383 shares of the pharmaceutical company’s stock valued at $1,944,119,000 after buying an additional 599,586 shares in the last quarter. Hedge funds and other institutional investors own 94.85% of the company’s stock.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down 0.14% during mid-day trading on Tuesday, hitting $114.65. The stock had a trading volume of 1,136,506 shares. The stock’s market cap is $28.48 billion. Vertex Pharmaceuticals Incorporated has a 12 month low of $71.46 and a 12 month high of $117.65. The stock’s 50-day moving average price is $99.06 and its 200-day moving average price is $86.82.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Wednesday, January 25th. The pharmaceutical company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.29 by $0.06. Vertex Pharmaceuticals had a negative return on equity of 2.15% and a negative net margin of 6.76%. The firm had revenue of $458.71 million for the quarter, compared to the consensus estimate of $453.40 million. During the same quarter last year, the company earned $0.17 earnings per share. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post $1.62 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.dailypolitical.com/2017/04/18/reliance-trust-co-of-delaware-sells-167-shares-of-vertex-pharmaceuticals-incorporated-vrtx.html.

Several equities research analysts have recently weighed in on VRTX shares. JMP Securities reiterated an “outperform” rating and set a $103.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday, December 23rd. Vetr upgraded Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $90.91 price target on the stock in a research report on Monday, January 9th. Robert W. Baird reiterated a “buy” rating and set a $115.00 price target on shares of Vertex Pharmaceuticals in a research report on Monday, January 9th. Zacks Investment Research upgraded Vertex Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $102.00 price target on the stock in a research report on Tuesday, March 28th. Finally, Credit Suisse Group AG set a $100.00 price target on Vertex Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 20th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $108.37.

In related news, CMO Jeffrey Chodakewitz sold 13,750 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, March 29th. The stock was sold at an average price of $106.65, for a total transaction of $1,466,437.50. Following the sale, the chief marketing officer now owns 136,261 shares of the company’s stock, valued at approximately $14,532,235.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Paul M. Silva sold 1,688 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, March 29th. The shares were sold at an average price of $106.30, for a total value of $179,434.40. Following the sale, the senior vice president now directly owns 21,759 shares in the company, valued at approximately $2,312,981.70. The disclosure for this sale can be found here. Insiders have sold a total of 106,250 shares of company stock worth $11,473,856 in the last three months. 1.90% of the stock is owned by corporate insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.